NEW YORK (GenomeWeb News) – Genomas has won a $1.4 million grant from the National Institutes of Health to develop pharmacogenomic technology that will help doctors predict drug efficacy and side-effect risk for neuropsychiatric disease patients.
The company plans to use the Small Business Innovation Research grant to continue developing its PhyzioType Systems, which use genetic polymorphisms found through array genotyping and an algorithm to help doctors develop personalized drug prescriptions for antidepressants and antipsychotics.
The research program integrates Genomas' physiogenomics technology with fMRI research developed at Hartford Hospital's Institute of Living and neuro-informatics studies conducted at the Mind Research Network and the University of New Mexico.
The technology "will open significant new avenues for interdisciplinary translational research and commercial strategic partnering in clinical neuroscience," Gualberto Ruano, Genomas' CEO and president and director of genetics research at Hartford Hospital, said in a statement.
Genomas, which is based on the campus of Hartford Hospital, has now secured a total of $4.8 million in NIH funding to develop the PhyzioType.